SEAGEN NASDAQ: SGEN
Background of Seagen
- Seagen, Inc. is a biotechnology company which is based in the United States, focussing on the development and commercialising of innovative, empowered monoclonal antibody-based therapies in the treatment of cancer.
- Seagen, Inc. traces its history back to 1997 and it is a leader in the industry where antibody-drug conjugates (ADCs) are concerned.
- ADCs refer to a technology specifically designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs intend to spare non-targeted cells, reducing many toxic effects of conventional chemotherapy while it potentially enhances antitumor activity.
- Seattle Genetics (Seagen, Inc.) was established in 1997 by Clay Siegall and by 1999, Seagen, Inc. started its research into anti-CD30 antibodies.
- In March 2001, Seagen, Inc. completed its initial public offering (IPO) where it started trading its shares on the Nasdaq stock market under the stock symbol SGEN. During the same year, Seagen, Inc. scientists synthesize monomethyl auristatin E (MMAE), the cytotoxic drug payload designed for the first antibody-drug conjugate (ADC), brentuximab vedotin (ADCETRIS).
- In 2006, the first patient was treated with ADCETRIS and in 2007, Seagen, Inc. and Agensys entered a collaboration which resulted in co-development of Enfortumab vedotin, which is an ADC that targets Nectin-4.
- In February 2009 Seagen, Inc. started a pivotal trial for Brentuximab vedotin for Hodgkin lymphoma. Phase II trial was started in June and by July the re-treatment clinical trial was initiated. Phase III trial for Brentuximab vedotin for post-transplant Hodgkin Lymphoma initiated in April 2010.
- In August 2009, Seagen, Inc. collaborated with MedImmune and in September there was collaboration with Bayer for the submission of investigational new drug application with the FDA.
- ADCETRIS was approved by the FDA in 2011 for relapsed classical Hodgkin lymphoma (cHL) as well as relapsed systemic anaplastic large cell lymphoma (ALCL).
- In 2011, Seagen, Inc. entered collaboration with Pfizer, Millennium Pharmaceuticals, Abbott, Genmab, and Oxford BioTherepeutics. Seagen, Inc. saw several drugs enter and complete several phases and in 2012, Seagen, Inc. initiated a global phase III of ADCETRIS against CD30-expressing cutaneous T-cell lymphoma.
- By November 2012, Seagen, Inc. had received orphan drug destination for ADCETRIS treatment of mycosis fungoides. During the same year, ADCETRIS was approved in the European Union (EU) for patients who presented with classical Hodgkin lymphoma (cHL).
- In September 2014, Brentuximab vedotin was successfully used as consolidation therapy in a late-stage for patients who had a type of lymphatic cancer.
- Seagen, Inc. expanded access to ADC technology in 2015 through collaborations with global biotechnology and pharmaceutical industry leaders and in 2016, Seagen, Inc. opens headquarters in Zug, Switzerland.
- By 2016, Seagen, Inc. was at the bottom of the Annual Top 25 Biotech Companies for the year, judged by staff of Genetic Engineering & Biotechnology News. In March 2016, Seagen, Inc. announced that it would develop 12 more drugs and extend its staff compliment by 100 employees.
- ADCETRIS was approved in the United States in 2017 for primary cutaneous ALCL or CD30-expressing mycosis fungoides, which is the most typical type of cutaneous T-cell lymphoma (CTCL).
- In 2018, ADCETRIS is approved in the United States in combination with chemotherapy for stage 3 or 4 cHL which was previously untreated. In addition, ADCETRIS is also approved in combination with chemotherapy with sALCL or other CD30-expressing peripheral T-cell lymphomas (PTCL) which was previously untreated.
- In 2019, ADCETRIS is established as a foundation of care, especially for certain types of CD30-expresing lymphomas, leading to its approval in more than 70 countries.
- Seagen, Inc.’s product portfolio consists of several different drugs including ADCETRIS, SGN-75, ASG-5ME, Enfortumab vedotin, and SGN-CD19A.
- Today, Seagen, Inc. is considered an industry leader biotechnology company which is headquartered in Washington, United States, with more than 1,605 employees who form its staff compliment.
Seagen Shares Growth Driver
- Seagen, Inc. is an industry-leader in antibody-drug conjugates or ADCs, with the flagship product Adcetris, which is commercially available for four different indicators in over 65 countries which includes the United States, Canada, Japan, and members of the European Union.
- ADCETRIS was approved for use in more than 70 countries in 2019, forming a foundation of care for certain types of CD30-expressing lymphomas.
- Seagen, Inc. has seen the approval of ADCETRIS, PADCEV, and TUKYSA, respectively, between 2011 and 2025.
- There are many who have given their testimonials on how Seagen, Inc.’s products have changed their life for the better in the fight against cancer.
- Seagen, Inc. is consistently working towards developing a new generation of targeted, empowered treatments which will inevitably advance cancer care.
- The pipeline that Seagen, Inc. has designed keeps patients in mind, focussing on therapies which have the potential to address crucial unmet medical needs.
- Seagen, Inc. is a global, multi-product biotechnology company which discovers, develops, and commercialises transformative medicine which target cancer, attempting to make a meaningful difference in the lives of people.
- In July, Seagen, Inc. received regular approval with indication expanded for PADCEV by the United States FDA.
Seagen Investor Tip
- Seagen, Inc. trades its shares on the NASDAQ Stock Market (NASDAQ) under the stock symbol SGEN. Seagen, Inc. forms part of the NASDAQ-100
- An analysis on the market performance for the second quarter, which ended in June, shows that total net product sales were to the value of $347.3 million (5 billion ZAR), which indicates a 44% increase from the same period in 2025, with ADCETRIS having sold the most, showing a 9% increase, followed by PADCEV with 44% increase, and TUKYSA with a 427% increase.
- The royalty revenues for the second quarter of 2025 as well as Year-to-Date in 2025 were $36.3 million (528 million ZAR) and $63.5 million (923 million ZAR), respectively.
- Amounts which were earned from Seagen, Inc.’s product, development, and technology collaborations were $4.8 million (69 million ZAR) in the first quarter and $7 million (101 million ZAR) for the Year-to-date in 2025.07.
- The collaboration revenues earned for the year-to-date in 2025 included a regulatory milestone associated with Policy in collaboration with Roche.
- As of June 30, Seagen, Inc. had $2.5 billion in (36.3 billion ZAR) in cash and investments.
- Where the forecast in figures is concerned for the remainder of 2025, Seagen, Inc. expects net product sales from ADCETRIS at $700 million (10.1 billion ZAR), PADCEV at $325 million (4.7 billion ZAR), and TUKYSA at $315 million (4.5 billion ZAR).
- During July, Seagen, Inc. and Astellas announced that the FDA granted PADCEV regular approval. The FDA also approved a new indication for adult patients with locally advanced or metastatic urothelial cancer. This relates to those who were previously ineligible for cisplatin-containing chemotherapy and who have previously received one or more lines of therapy.
- Data from the analysis should be weighed against forecasted performance during this pandemic, but for now, prices on shares and in turn dividends remain unaffected, which provides shareholders with assurance that they will have a strong buy-in on NASDAQ.
Sector
Healthcare
Industry
Biotechnology
Sub industry
Pharmaceutical
Latest News
Seagen: How to buy Seagen Shares Online
Here are the steps you need to follow to buy Seagen, Inc. shares with utmost confidence:
- Navigate to the AvaTrade website and select ‘Register’.
- Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
- As soon as your account application has been reviewed and approved, you can select your trading platform from AvaTrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
- Once you have downloaded the trading platform of your choice, you can use your AvaTrade live account details to log into your AvaTrade account on the trading platform.
- From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select ‘SGEN’ to buy/purchase shares.
- Alternatively, you can make use of AvaTrade’s online Web Trader or the AvaTradeGo mobile application.
Trading CFDs and Stocks with AvaTrade provides traders with the following benefits:
- Leverage of up to 1:20.
- Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
- Indices, stocks, and commodities can all be traded form a single screen.
- Client support is presented live in a multitude of languages.
- Traders have exclusive access to a variety of educational tools.
- Trades can be executed across multiple platforms.
More shares that can be purchased through AvaTrade, can be viewed here.
FAQ
Can I buy Seagen, Inc. shares in South Africa?
Yes, you can.
How to buy Seagen, Inc. shares?
By simply opening a free account with SA Shares, or by clicking the “Buy this Share” button to get started.
What is the current share price?
By clicking on the link provided above, you can view the real-time Seagen, Inc. share price on the platform.
Is Seagen, Inc. a good share to buy?
Yes, it is. Seagen, Inc. is experiencing solid and improved financial performance, with this set to continue in the last two quarters of the year.
Can I buy Seagen, Inc. CFD through SA Shares?
Yes, you can.
Top 4 Brokers
